Communiqués Madrigal Pharmaceuticals, Inc.

Actions

MDGL

US5588681057

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Autres places de cotation 22:00:00 13/07/2026			Varia. 5j.	Varia. 1 janv.
531,00 ^USD	-1,06%		+0,29%	-8,82%

13/07	Madrigal Pharmaceuticals : trois nouveaux brevets soutiennent une extension de protection jusqu'en 2045, selon Truist	MT
13/07	Madrigal Pharmaceuticals renforce la protection de son médicament Rezdiffra avec trois nouveaux brevets	MT

Communiqués

13/07	Madrigal Pharmaceuticals Announces Three New Resmetirom Patents, Strengthening IP Portfolio	AQ
06/07	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
22/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
04/06	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
03/06	Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026	AQ
27/05	Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH	AQ
21/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
20/05	Madrigal to Present New Data from the Company’s MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk	AQ
07/05	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
06/05	Madrigal Pharmaceuticals : MDGL 1Q26 Earnings Presentation	PU
06/05	Madrigal Pharmaceuticals : 1Q26 Press Release Final	PU
06/05	Madrigal: Q1 Earnings Snapshot	AQ
06/05	Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates	AQ
05/05	Madrigal Adds Clinical-Stage siRNA Asset Targeting PNPLA3 to its MASH Pipeline	AQ
22/04	Madrigal Pharmaceuticals to Release First-Quarter 2026 Financial Results and Host Webcast on May 6, 2026	AQ
21/04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
07/04	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
19/03	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
05/03	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ
24/02	Madrigal Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference	AQ
19/02	Madrigal Pharmaceuticals : MDGL 4Q25 Earnings Presentation 02.19.26	PU
19/02	Madrigal: Q4 Earnings Snapshot	AQ
19/02	Madrigal Pharmaceuticals : 4Q25 Press Release 02.19.26	PU
19/02	Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results	AQ
17/02	Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)	AQ